Posted by Michael Wonder on 04 Apr 2022
Biocon Biologics’ partner receives positive EU CHMP opinion for biosimilar human insulin for IV infusion
1 April 2022 - Celerity Pharmaceuticals Uses Biocon Biologics’ Insulin Drug Substance to Develop the Product.
Biocon Biologics announced today the European Medicines Agency’s CHMP has adopted a positive opinion, recommending the granting of a marketing authorisation for Inpremzia, a biosimilar version of Actrapid (human insulin).
